On the other hand, bone restoration and the increased bone formation in diabetes by the anti-sclerostin antibody are accompanied by decreased resorption, consistent with the profile of Scl-Ab in preclinical33 and clinical studies with osteoporotic patients.37,38. This evidence concerns the gene SOST and diabetes mellitus.